Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 15/20 | 0.48 |
| ▸ | BRD4 | O60885 | 4/20 | 0.48 |
| ▸ | BRDT | Q58F21 | 4/20 | 0.48 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.44 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544473 | 0.92 | PLK1 (0.59) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL3539402 | 0.91 | PLK1 (0.58) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL3542042 | 0.89 | PLK1 (0.58) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL3545374 | 0.85 | PLK1 (0.54) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL3544894 | 0.84 | PLK1 (0.60) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL1560256 | 0.84 | PLK1 (0.70) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL3544005 | 0.83 | PLK1 (0.50) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL3550663 | 0.82 | PLK1 (0.60) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL3543888 | 0.82 | PLK1 (0.58) | PLK1BRD4BRDTPLK3PLK2 | |
| SCHEMBL3545297 | 0.81 | PLK1 (0.62) | PLK1BRD4BRDTPLK3PLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709471-B2 | Compounds | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080009482-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009482-A1 | NOVEL COMPOUNDS | CYP11B2, CYP11B1, CYP46A1 | PLK1 847/4885BRD4 2662/4885BRDT 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.